Remarkably, the frequency of EZH2 expressing Treg among the CD39+, TNFR2+ and TNFR2+CD39+ Treg populations were lower in axSpA patients than in HD (Supplementary Figures S2E–G). This evidence concerns the gene EZH2 and Huntington disease.